FibroBiologics, Inc. — Form SCHEDULE 13D
Filed September 17, 2026 · analyzed by the Ownership Agent
SCHEDULE 13D
— Neutral
significance 18/100
What the filing says
Khoja Hamid filed a Schedule 13D on 2026-09-17 regarding acquisition of beneficial ownership in FibroBiologics, Inc. (public market cap ~$21.6M). The filing header does not display the specific share count, percentage ownership, or dollar amount of the acquisition in the provided text extract. Concrete transaction details are not accessible in this portion of the document.
Why this rating
Schedule 13D filings are routine disclosure requirements when beneficial ownership crosses 5%. Without disclosed share count, percentage, or price, cannot assess materiality; likely routine threshold-triggered filing.
See more from September 17, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.